Jason Butler
Stock Analyst at Citizens
(4.67)
# 183
Out of 5,055 analysts
143
Total ratings
52.74%
Success rate
43.57%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $70.03 | +31.37% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $5.39 | +122.63% | 8 | Oct 9, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $29 → $11 | $9.93 | +10.78% | 11 | Sep 2, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $33 → $95 | $110.39 | -13.94% | 4 | Jul 23, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $24.34 | +15.06% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $24.02 | +54.04% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $14.00 | +178.57% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $4.85 | +23.71% | 11 | Jun 12, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $41.93 | +138.49% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $28.77 | +32.08% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $78 | $66.44 | +17.40% | 16 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $8.88 | +102.70% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.90 | +37.93% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $907.98 | -22.80% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $11.06 | +198.37% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $9.87 | -8.81% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.52 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $11.24 | +69.04% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $3.14 | +600.64% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.11 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $15.03 | +279,341.12% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $12.05 | +862.66% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.52 | +99.12% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.31 | - | 1 | Dec 2, 2020 |
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $70.03
Upside: +31.37%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $5.39
Upside: +122.63%
Prothena Corporation
Sep 2, 2025
Maintains: Market Outperform
Price Target: $29 → $11
Current: $9.93
Upside: +10.78%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Market Outperform
Price Target: $33 → $95
Current: $110.39
Upside: -13.94%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $24.34
Upside: +15.06%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $24.02
Upside: +54.04%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $14.00
Upside: +178.57%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $4.85
Upside: +23.71%
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $41.93
Upside: +138.49%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $28.77
Upside: +32.08%
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $66.44
Upside: +17.40%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $8.88
Upside: +102.70%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.90
Upside: +37.93%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $907.98
Upside: -22.80%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $11.06
Upside: +198.37%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $9.87
Upside: -8.81%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.52
Upside: -
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $11.24
Upside: +69.04%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $3.14
Upside: +600.64%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $4.11
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $15.03
Upside: +279,341.12%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $12.05
Upside: +862.66%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.52
Upside: +99.12%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.31
Upside: -